Unity Confirm captures follow-on revenue

Unity Confirm matters because it lets BillionToOne make more money from the same prenatal account by adding a follow on billable test exactly where standard NIPT usually hands off to invasive procedures. OBs already ordering UNITY can keep the patient inside the same blood draw based workflow when a result comes back high risk, instead of losing the next step to maternal fetal medicine and procedure based diagnostics.1 2 3 4

• The workflow slot is specific. Standard NIPT is a screening test, and high risk results are typically followed by CVS or amniocentesis for confirmation. Natera’s own patient materials describe that handoff. Unity Confirm inserts a new option between those two steps for patients who decline or cannot access an invasive procedure.2 5 6
• This is attractive commercially because it does not require BillionToOne to win a new specialty channel first. The company already sells prenatal tests into OB/GYNs, hospitals, and fertility clinics. A confirmation assay offered to the same prescriber base raises revenue per positive case without rebuilding the field force from scratch.1 3 4
• The product also changes the technical posture of the second test. Instead of reading placental DNA fragments in maternal blood, Unity Confirm isolates intact fetal cells and sequences individual cells. BillionToOne positions that as closer to a diagnostic style readout while keeping the sample collection to another maternal blood draw.2 3 6

Going forward, the prize is not just share in first line screening, but ownership of the full prenatal decision tree after a positive result. If BillionToOne can make confirmation a routine second order inside existing practices, it can increase revenue per pregnancy and make UNITY harder for competing prenatal screens to displace.1 2 4